ASO-5005

ASO-5005 effectively downregulates the mRNA levels of Bcl-2 and Bcl-xL in MDA-MB-231 breast cancer cells, with an IC₅₀ value of 65 nM for Bcl-2 and an IC₅₀ value of 97 nM for Bcl-xL^[1].
ASO-5005 (2 h)-mediated downregulation of Bcl-xL mRNA in MDA-MB-231 breast cancer cells is first detectable as early as 2 hours post-treatment and increases over time^[1].
ASO-5005 downregulates Bcl-2 and Bcl-xL mRNA in H125 non-small cell lung cancer cells, with an IC₅₀ value of 71 nM for Bcl-2 and an IC₅₀ value of 80 nM for Bcl-xL^[1].
ASO-5005 does not significantly alter the expression of the off-target genes Bcl-W, survivin, Akt and p53 in MDA-MB-231 breast cancer cells^[1].
ASO-5005 (150-300 nM; 6 h of initial culture plus 42 h of culture after medium change, for a total of 48 h) reduces Bcl-2 and Bcl-xL protein levels in MDA-MB-231 breast cancer cells and H125 non-small cell lung cancer cells at concentrations of 150 nM and 300 nM^[1].
ASO-5005 reduces the viability of MDA-MB-231 breast cancer cells and H125 non-small cell lung cancer cells, with morphological evidence of apoptosis^[1].
ASO-5005 (50-100 nM; 72 h) sensitizes MDA-MB-231 breast cancer cells and H125 non-small cell lung cancer cells to a variety of anticancer agents, and reduces cell viability to a greater extent than single-agent treatment^[1].
ASO-5005 (50-100 nM) induces caspase-3 activation and enhances chemotherapy-induced Caspase-3 activation in both MDA-MB-231 breast cancer cells and H125 non-small cell lung cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.